相关实验视频
Updated: Jul 12, 2025

11:10
Isolation of Human Islets from Partially Pancreatectomized Patients
Published on: July 30, 2011
16.3K
发生感染的风险取决于胰岛素治疗2型糖尿病患者的口服抗糖尿病药物暴露
Sanghwa Park1, Jiseon Jeong1, Yunna Woo1
1College of Pharmacy, Ajou University, Suwon, Republic of Korea.
Scientific reports
|October 27, 2023
概括
双二酶-4抑制剂 (DPP4is) 在接受胰岛素治疗的2型糖尿病患者中没有增加感染风险. 与甲胺相比,糖携带载体-2 抑制剂 (SGLT2is) 显示生殖器感染的风险较高,但尿路感染的风险较高.
科学领域:
- 内分泌学 在内分泌学.
- 药理学 药理学是指药理学的学科.
- 传染病流行病学 传染病流行病学
背景情况:
- 2型糖尿病 (T2DM) 与感染风险增加有关.
- 双基酸酶-4抑制剂 (DPP4is) 和糖携运输体-2抑制剂 (SGLT2is) 是常用的T2DM药物.
- 有关DPP4is和SGLT2is增加T2DM患者感染风险的潜力存在担忧.
研究的目的:
- 调查DPP4is和SGLT2is与胰岛素治疗T2DM患者感染风险的相关性.
- 为了比较DPP4is和SGLT2is的感染风险与接受胰岛素治疗的T2DM患者的甲福明.
主要方法:
- 一项使用韩国医疗保险数据的回顾性队列研究.
- 使用倾向分数匹配来创建可比较的组.
- 分析了感染结果,包括呼吸道,生殖器和尿路感染 (UTI).
主要成果:
- 与甲胺相比,DPP4抑制剂 (DPP4is) 与感染风险的增加无关.
- 糖携带体-2 抑制剂 (SGLT2is) 与发生性感染的风险显著增加有关 (OR 1.76,p=0.03).
- 与甲福明相比,SGLT2is没有检测到尿路感染的风险增加. 在男性中,呼吸道感染的风险降低 (OR 0.77,p=0.04).
结论:
- DPP4is似乎不会增加胰岛素治疗T2DM患者的感染风险.
- 在这个人群中,SGLT2与生殖器感染的风险增加有关.
- 需要进一步的研究来阐明SGLT2i相关的生殖器感染背后的机制.
相关概念视频
Oral Hypoglycemic Agents: Glinides
160
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
160
Oral Hypoglycemic Agents: Biguanides and Glitazones
212
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
212
Diabetes Mellitus: Type 2 and Gestational
2.5K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
2.5K
Diabetes Mellitus: Overview and Type I Subtype
2.7K
Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
2.7K
Insulin: Dosing Regimen and Adverse Effects
184
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
184
Oral Hypoglycemic Agents: Sulfonylureas
215
Sulfonylureas are oral hypoglycemic agents utilized in treating type 2 diabetes. They are characterized by their unique sulfonylurea chemical structure. The family of sulfonylureas is divided into generations. First-generation sulfonylureas, including tolbutamide (Orinase), chlorpropamide (Diabinese), and tolazamide (Tolinase), trigger insulin release from pancreatic β cells and enhance peripheral tissues' insulin sensitivity. The second-generation members, such as glipizide...
215

